From JPMA From the "Pharmaceutical Association of Japan Press Conference
1. Summary of "Necessity of Industrial Policy in the Pharmaceutical Industry
We believe that it is necessary to promote measures against infectious diseases from normal times as part of the COVID-19 convergence and the reinforcement of measures against new infectious diseases that will come in the future. Furthermore, we believe that sound growth of the domestic pharmaceutical industry is essential for the creation of domestically produced vaccines and therapeutics, and that it is necessary to promote industrial policy by positioning the pharmaceutical industry as a fundamental and core industry of the country.
Now, Japan is trying to promote DX (Digital Transformation) and move toward the realization of "Society 5.0" and "Data-driven Society". We believe that the life science sector, in addition to the digital and green sectors, should definitely be included as a sector that will play a role in the post-corona economic recovery.
Japan Pharmaceutical Manufacturers Association
Chairman Joji Nakayama
2. Summary of "The Pharmaceutical Manufacturers Association of Japan (Pharmaceutical Manufacturers Association of Japan) Policy Proposal 2021
COVID-"The Pharmaceutical Manufacturers Association of Japan (JPMA) Policy Proposal 2021" outlines the vision of the pharmaceutical industry. First of all, it is necessary to establish a system that can predictably achieve both "promotion of innovation" and "sustainability of universal health coverage" even under the severe financial situation of the social security system. We would also like to establish a system in which the various values of pharmaceuticals and their value based on the evidence newly established after marketing are appropriately evaluated, and in which companies proactively explain their value and gain a high degree of acceptance and trust from the public.
The Pharmaceutical Manufacturers Association of Japan and its member companies will continue to do their utmost to save as many patients suffering from illnesses as possible, even a day sooner, and to ensure a brighter future for both patients and the world. To achieve this, we need an environment where innovation can be created and where innovation is properly evaluated, and we will strive to gain the understanding of all sides.
(From the Pharmaceutical Manufacturers Association Newsletter, May 2021, No. 203, Top News)
Japan Pharmaceutical Manufacturers Association (JPMA)
The Pharmaceutical Manufacturers Association of Japan (PMAJ), founded in 1968, is an association of R&D-oriented pharmaceutical companies that aim to contribute to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
The organization is dedicated to promoting a deeper understanding of pharmaceuticals and providing policy recommendations for the sound development of the pharmaceutical industry, with the aim of realizing patient-participatory medicine.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Manufacturers Association of Japan (PAPJ) is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
The Japan Pharmaceutical Manufacturers Association aims to contribute to society through the development of new drugs